Skip to main content
Fig. 2 | Trials

Fig. 2

From: Safety and effectiveness of delivering mass drug administration for helminths through the seasonal malaria chemoprevention platform among Senegalese children: study protocol for a randomised controlled trial

Fig. 2

Schematic diagram of the study design: A day before the commencement of the first cycle of SMC, 600 eligible children aged 1–14 years will be randomly assigned to one of three arms at a ratio of 1:1:1 to determine the safety, feasibility and tolerability of the SMC and anthelminthic drug co-administration. The first group will receive vitamin A and zinc supplement and the second group will receive praziquantel and vitamin A while the third group will receive albendazole and praziquantel. On the following day, corresponding to the start (day 1) of the first SMC cycle, all the three groups will receive amodiaquine (AQ) and sulphadoxine/pyrimethamine (SP) according to the WHO and Senegal SMC implementation guidelines. On the second and third day of the SMC cycle, all study children in the three groups will receive AQ, in line with the SMC guidelines

Back to article page

Trials

ISSN: 1745-6215